Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TROY-Ig
- Development stage
- Unknown
- Lead developer
- Lijin Biomedical Technology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TROY-Ig (also known as xLinkTsAb) is a bispecific T-cell engager (TCE) platform developed by Lijin Biomedical Technology (Lyvgen). It is designed to treat a variety of tumor antigen (TA)-positive tumors by simultaneously targeting CD3 and the costimulatory receptor CD137 (4-1BB) on T cells, while also binding to specific tumor antigens such as CD19, CD20, B7H3, DLL3, or PSMA. This dual-signaling approach aims to enhance T-cell activation, proliferation, and persistence within the tumor microenvironment, potentially overcoming the limitations of conventional CD3-based engagers. The platform is currently in Phase 1 clinical development for the treatment of broad TA-positive malignancies.
- Other names
- TROY-Ig platformxLinkTsAb platform
02
Targets
TNFRSF9 (CD137 extracellular domain)CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TROY-Ig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TROY-Ig.